BioCentury
ARTICLE | Clinical News

RHB-104: Phase III started

October 7, 2013 7:00 AM UTC

RedHill began the double-blind, placebo-controlled, international Phase III MAP US trial to evaluate oral RHB-104 twice daily for 52 weeks in about 240 patients with moderately to severely active CD. ...